loading
Precedente Chiudi:
$20.98
Aprire:
$21
Volume 24 ore:
106.45K
Relative Volume:
0.43
Capitalizzazione di mercato:
$327.33M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-21.90
EPS:
-0.99
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
-1.76%
1M Prestazione:
+9.10%
6M Prestazione:
-6.02%
1 anno Prestazione:
+238.69%
Intervallo 1D:
Value
$20.62
$22.12
Intervallo di 1 settimana:
Value
$19.12
$22.29
Portata 52W:
Value
$4.00
$31.01

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name
Nome
Jasper Therapeutics Inc
Name
Telefono
(650) 549-1400
Name
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Name
Dipendente
45
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
JSPR's Discussions on Twitter

Confronta JSPR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
JSPR 21.68 327.33M 0 -64.47M -52.33M -0.99
VRTX 450.67 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.00 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 590.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.51 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.00 24.89B 3.30B -501.07M 1.03B 11.54

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-08-11 Iniziato CapitalOne Overweight
2022-02-28 Iniziato Cantor Fitzgerald Overweight
2021-11-08 Iniziato Credit Suisse Outperform
2021-10-21 Iniziato William Blair Outperform
2021-10-20 Iniziato BMO Capital Markets Outperform
2021-10-13 Iniziato Oppenheimer Outperform
Mostra tutto

Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie

pulisher
Nov 18, 2024

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 16, 2024

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Yahoo Finance

Nov 16, 2024
pulisher
Nov 16, 2024

Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey

Nov 16, 2024
pulisher
Nov 14, 2024

10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey

Nov 14, 2024
pulisher
Nov 13, 2024

Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes mast cell stock - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Jasper Therapeutics to Present Briquilimab Updates at Major Healthcare Conferences | JSPR Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86 - MarketBeat

Nov 12, 2024
pulisher
Nov 10, 2024

Stifel Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) News: Jasper Therapeutics, Inc. Reports Third Quarter 2024 Results - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Jasper Therapeutics Advances in Antibody Therapy Development - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Jasper Therapeutics Inc (JSPR) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Nasdaq Other Finance Index (OFIN) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 06, 2024

(JSPR) Long Term Investment Analysis - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 04, 2024

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire

Nov 04, 2024
pulisher
Nov 03, 2024

Net Present Value Model: Jasper Therapeutics Inc’s Briquilimab - GlobalData

Nov 03, 2024
pulisher
Oct 27, 2024

JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 27, 2024
pulisher
Oct 26, 2024

Long Term Trading Analysis for (JSPR) - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 25, 2024

Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com

Oct 25, 2024
pulisher
Oct 24, 2024

Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Jasper Therapeutics to Present Preclinical Briquilimab Data - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria - GlobeNewswire

Oct 23, 2024
pulisher
Oct 21, 2024

Molina Healthcare (MOH) Set to Announce Earnings on Wednesday - Defense World

Oct 21, 2024
pulisher
Oct 21, 2024

Analysts Set Rush Street Interactive, Inc. (NYSE:RSI) Target Price at $11.17 - Defense World

Oct 21, 2024
pulisher
Oct 18, 2024

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights

Oct 18, 2024
pulisher
Oct 17, 2024

Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright - Defense World

Oct 17, 2024
pulisher
Oct 17, 2024

Metagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 17, 2024
pulisher
Oct 17, 2024

JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

JMP Securities analysts initates a Mkt outperform rating for Jasper Therapeutics Inc (JSPR) - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Analysts review Ares Capital Corp’s rating - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Jasper Therapeutics shares keep buy rating with positive study results By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 15, 2024

DoubleVerify Holdings Inc [DV] stock was sold by Allais Nicola T at the price of US$30365.0 - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

When (JSPR) Moves Investors should Listen - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Jasper Therapeutics Inc (JSPR) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

Jasper gains 11% on data for briquilimab in urticaria (NASDAQ:JSPR) - Seeking Alpha

Oct 14, 2024
pulisher
Oct 14, 2024

Jasper Therapeutics shares hold as Oppenheimer maintains $80 target By Investing.com - Investing.com Canada

Oct 14, 2024
pulisher
Oct 14, 2024

Jasper Therapeutics shares hold as BTIG maintains $90 target By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

You Should Read This Analysis Before Investing in Jasper Therapeutics Inc (NASDAQ:JSPR) - US Post News

Oct 14, 2024
pulisher
Oct 14, 2024

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Jasper reports promising early results in urticaria study - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga

Oct 14, 2024
pulisher
Oct 14, 2024

Jasper Therapeutics Stock Gains on Strong Briquilimab Trial Results - MarketWatch

Oct 14, 2024
pulisher
Oct 14, 2024

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire

Oct 14, 2024
pulisher
Oct 14, 2024

Jasper reports promising early results in urticaria study By Investing.com - Investing.com UK

Oct 14, 2024

Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):